Skip to content

Hyperfine, Inc. HYPR Warrant Liabilities Long Term

Warrant Liabilities Long Term at other companies

Vor Biopharma logo
Vor BiopharmaVOR
$638.46M
FIP
FTAI Infrastructure Inc.FIP
$81.6M
NextNav logo
NextNavNN
$29.74M+38.8%
Palladyne AI Corp. logo
Palladyne AI Corp.PDYN
$3.82M-82.8%
Exagen Inc. logo
Exagen Inc.XGN
$767K
Archer Aviation logo
Archer AviationACHR
$7.1M-85.1%

Other financials

Income statement

See full
Revenue$3.9M+82.6%
Gross profit$2.0M+124%
Operating income-$8.6M+21.5%
Net income-$8.6M+8.4%
EPS (diluted)-$0.09+25.0%

Balance sheet

See full
Cash & equivalents$40.8M+23.2%
Total debt$13.4M+4,977%
Total equity$34.4M-20.3%
Total assets$60.3M+13.0%

Cash flow

See full
Operating cash flow-$9.0M+2.6%
CapEx$242.0K-48.7%
Free cash flow-$9.3M+4.8%

Valuation

See full
Market cap$129.05M+127%
Enterprise value$101.63M+220%
P/S8.4×+3.1×

Profitability

See full
Gross margin51.2%+5.0pp
Operating margin-226.6%-63.4pp
Net margin-226.9%-57.5pp
FCF margin-187%-52.9pp

Returns & leverage

See full
Return on equity-89.8%+42.9pp
Debt / equity0.4×+0.4×
Current ratio5.5×-0.5×

Where this comes from

Reported directly by Hyperfine, Inc. in its filing.

Tagged under the XBRL concept hypr:WarrantLiabilitiesLongTerm.

The official record: Hyperfine, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Hyperfine, Inc.'s warrant liabilities long term.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Hyperfine, Inc.'s warrant liabilities long term?
Hyperfine, Inc. (HYPR) reported warrant liabilities long term of $1.97M in Q1 2026.
How has Hyperfine, Inc.'s warrant liabilities long term changed year-over-year?
Hyperfine, Inc.'s warrant liabilities long term increased by 59.0% year-over-year, from $1.24M to $1.97M.
What does warrant liabilities long term mean?
This represents the fair value of outstanding warrants that are classified as liabilities rather than equity, with settlement expected beyond one year. These instruments often arise from financing activities and are subject to periodic revaluation based on changes in the company's stock price and volatility. It serves as a measure of potential future dilution or cash settlement obligations that impact the company's long-term capital structure.